These include the potential additional benefit when combining SGLT-2i with GLP1-RA, the benefits and harms of using SGLT-2i inhibitors in CKD patients with severely impaired eGFR (i.e., <20 or 30 mL/min/1.73 m2), the lack of validated tools assessing the baseline risk for all CV outcomes according to ethnicity, race, and geography, and the lack of studies assessing the effect of different diabetes drugs on life quality [109]. This evidence concerns the gene GLP1R and diabetes mellitus.